Home › Peptides › Retatrutide

Is Retatrutide safe?

Investigational

Retatrutide is an investigational drug with striking phase 3 weight-loss results but no approval. Any retatrutide sold online today is unauthorized, and US law bars it from compounding.

Unapproved, with substantial published trial data. No regulator has authorised it for any human use, so legally it sits exactly where an unapproved compound sits — but unlike most unapproved peptides it has been through registered human trials that have reported, so there is a real body of evidence on what it does and what goes wrong. What is missing is the long-term and post-approval record: the trials that surface uncommon or delayed harms have not finished, and nothing has been reviewed by a regulator.

Updated October 2026 · Checked against Eli Lilly (sponsor), FDA, Health Canada (Recalls & Safety Alerts), ClinicalTrials.gov

Name: Retatrutide
Also known as: LY3437943
Class: Triple GIP, GLP-1 and glucagon receptor agonist (investigational)
Verdict: Investigational Unapproved, with substantial published trial data
Human evidence: Strong
Updated: October 2026

What is Retatrutide?

Retatrutide is an experimental once-weekly injection developed by Eli Lilly. It activates three receptors (GIP, GLP-1 and glucagon), which is why it is called a triple agonist. The glucagon component is thought to increase energy expenditure on top of the appetite effects seen with semaglutide and tirzepatide. Lilly describes it as investigational and available only in clinical trials.

What it is claimed to do

These are the uses Retatrutide is promoted for. Listing a claim is not endorsing it — the next section is where each one meets the evidence.

Weight loss in adults with obesity or overweight
Blood sugar control in type 2 diabetes
Reducing pain and improving function in obesity with knee osteoarthritis

What the human evidence shows

Evidence: StrongMultiple randomised controlled trials in humans, or a systematic review of them, reporting consistent results on an outcome that matters.

This is an unusual case: the drug is unapproved, but the trial evidence is substantial. In TRIUMPH-1, an 80-week phase 3 trial of 2,339 adults with obesity or overweight and no diabetes (Lilly topline results, May 21, 2026), average weight loss rose with dose, from 19.0% in the lowest dose arm to 28.3% in the highest, versus 2.2% on placebo. Side effects were mainly digestive: nausea in 28.6% to 42.4% of participants depending on dose, versus 14.8% on placebo, with more vomiting and diarrhea at higher doses. Dysesthesia (abnormal skin sensations such as tingling) was reported in up to 12.5% of participants, versus 0.9% on placebo, and stopping treatment because of side effects rose to 11.3% in the highest dose arm. These are company-reported topline results; peer-reviewed publication and regulatory review are how they get independently scrutinized.

Known risks and side effects

Not yet reviewed for approval, so long-term safety and rare risks are not established.
In the TRIUMPH-1 results, common effects were nausea, diarrhea, constipation and vomiting, rising with dose.
Dysesthesia (unusual skin sensations) was reported much more often than on placebo.
Discontinuation because of side effects was higher in the highest dose arm (11.3%) than on placebo (4.9%).
Products sold online as retatrutide are not made under any regulatory oversight, so the identity, purity and dose of what is in the vial are unknown.

Legal status

Regulatory status as of October 2026. Approval, prescription status and compounding restrictions change without notice, and the two countries move independently. Check the regulator directly before relying on any of it.

United States

Approved for human use: No — not approved by the FDA for any human use
Prescription only: Not applicable or not yet determined

Not FDA approved. The FDA states that retatrutide has not been found safe and effective for any condition and that federal law bars its use in compounding. Lilly has not announced an approval date.

Canada

Approved for human use: No — not approved by Health Canada for any human use
Prescription only: Not applicable or not yet determined

Investigational. Lilly says it is available only in clinical trials, so any retatrutide offered online is unauthorized. Health Canada's January 2026 advisory warns about unauthorized GLP-1 products in general.

Who should avoid Retatrutide

You are considering buying it online: it is not an authorized product and cannot be legally compounded in the US.
You are interested in it for weight loss: ask a clinician about approved options, or about eligibility for a clinical trial.

Frequently asked questions

Is retatrutide safe?

That cannot be answered fully yet. Phase 3 results show frequent digestive side effects and other effects such as unusual skin sensations, but regulators have not reviewed the full data for approval. Unauthorized retatrutide sold online adds unknown quality risks.

Is retatrutide legal?

As an unapproved investigational drug it cannot be legally marketed as a medicine in the US or Canada. The FDA says federal law bars its use in compounding.

When will retatrutide be approved?

There is no confirmed approval date. Lilly describes it as investigational; approval would follow regulatory review of the phase 3 program.

Sources

Eli Lilly (sponsor)Eli Lilly: TRIUMPH-1 phase 3 topline results (May 21, 2026)
FDAFDA: concerns with unapproved GLP-1 drugs, including retatrutide
Health Canada (Recalls & Safety Alerts)Health Canada advisory on fake or unauthorized GLP-1 drugs (January 2026)
ClinicalTrials.govClinicalTrials.gov: TRIUMPH-1 (NCT05929066)

Browse all 16 peptides →

Educational information only. This page summarises published evidence and regulatory records about Retatrutide. It is not medical advice, it is not a recommendation for or against use, and it cannot account for your history, medications or conditions — that is a conversation for a licensed clinician.We sell nothing, name no seller, and carry no affiliate or vendor links. See the full disclaimer and ourmethodology.